Stroke remains a significant unmet clinical need with few treatment options that have a very
narrow therapeutic window, thereby causing massive mortality and morbidity in the United …

Ischemic vascular diseases remain leading causes of disability and death. Although various
clinical therapies have been tried, reperfusion injury is a major issue, occurring when blood …

Animal model studies and first clinical trials have demonstrated the safety and efficacy of the
mesenchymal stem cells'(MSCs) transplantation in stroke. Intra-arterial (IA) administration …

Background In order to promote the clinical translation of preclinical findings, it is imperative
to identify the most optimal therapeutic conditions and adopt them for further animal and …

Systemic transplantation of mesenchymal stem cells (MSCs) is a promising approach for the
treatment of ischemia-associated disorders, including stroke. However, exact mechanisms …

Stroke is the third leading cause of years lost due to disability and the second-largest cause
of mortality worldwide. Most occurrences of stroke are brought on by the sudden occlusion of …

Strokes within pediatric populations are considered to be the 10th leading cause of death in
the United States of America, with over half of such events occurring in children younger …

Despite the reality that a death from cerebrovascular accident occurs every 3.5 min in the
United States, there are few therapeutic options which are typically limited to a narrow …

This study is designed to determine the efficacy of Cerebrolysin treatment as an add-on
therapy to mechanical thrombectomy (MT) in reducing global disability in subjects with acute …

Stroke is a debilitating neurovascular injury that those effects hundreds of thousands of
Americans each year. Despite the high prevalence, disease morbidity and mortality, options …